SCHEMBL5149138

SCHEMBL5149138

CC(C)n1nc(-c2nc(-n3cncn3)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
POLB P06746 2/20 0.36
ALDH1A1 P00352 1/20 0.36
ADORA2A P29274 1/20 0.33
TP53 P04637 1/20 0.32
FGFR1 P11362 3/20 0.32
FGFR2 P21802 3/20 0.32
FGFR3 P22607 3/20 0.32
SRC P12931 5/20 0.32
PIK3CD O00329 4/20 0.32
ABL1 P00519 4/20 0.32
PIK3CA P42336 4/20 0.32
PIK3CB P42338 4/20 0.32
PIK3CG P48736 4/20 0.32
PRKDC P78527 4/20 0.32
PDE2A O00408 1/20 0.32
RET P07949 2/20 0.32
BMPR1B O00238 1/20 0.31
BMPR1A P36894 1/20 0.31
TGFBR1 P36897 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5150818 0.87 LMNA (0.41) LMNAPOLBALDH1A1ADORA2AFGFR1
SCHEMBL5152752 0.86 ADORA2A (0.37) POLBALDH1A1ADORA2ATP53FGFR1
SCHEMBL6134625 0.84 LMNA (0.44) LMNAPOLBALDH1A1ADORA2ATP53
SCHEMBL5152563 0.82 ADORA2A (0.37) POLBADORA2ATP53FGFR1FGFR2
SCHEMBL5149236 0.82 TSHR (0.35) LMNAALDH1A1ADORA2ATP53
SCHEMBL5147958 0.81 ADORA2A (0.39) LMNAPOLBALDH1A1ADORA2ATP53
SCHEMBL5152699 0.81 MAPT (0.40) LMNAALDH1A1ADORA2ATP53PIK3CG
SCHEMBL5149031 0.80 ALDH1A1 (0.41) LMNAALDH1A1ADORA2APIK3CG
SCHEMBL5149110 0.80 PDE1A (0.41) LMNAPOLBALDH1A1ADORA2ATP53
SCHEMBL5149086 0.79 ADORA2A (0.36) POLBADORA2ATP53FGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US claimed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US claimed
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 LMNA 2809/4885POLB 2847/4885ALDH1A1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.